TxCell to provide update on immunotherapy products at Société Générale Healthcare & Biotechnology Conference

TxCell SA (FR0010127662 – TXCL), a biotechnology company developing innovative, personalized cell-based immunotherapies using antigen specific regulatory T-cells (Ag-Tregs) for severe chronic inflammatory and autoimmune diseases, announces today that it will participate at the Société Générale Healthcare & Biotechnology Conference. The conference will be held in Paris on the 24^th September 2014.

At the conference, TxCell’s CEO, Damian Marron will give an update on the status and progress for the company's portfolio of economically viable personalized cell-based immunotherapy products in a range of group and one on one meetings with investors.

“The Société Générale Healthcare & Biotechnology Conference is an important date in the calendar for a wide range of investors and as a result will be an ideal occasion to provide updates to investors on the progress of TxCell,” said Damian Marron, CEO, TxCell. “This includes actions TxCell has taken since our introduction on the Paris Euronext markets. We will also discuss developments concerning our innovative proprietary technological platform ASTrIA of personalized cell-based immunotherapies for severe chronic inflammatory and autoimmune diseases.”